Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

884.48 -1.46 (-0.16%)
Official Closing Price Updated: 4:10 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,451,030
Open 888.83
Bid (Size) 881.46 (1)
Ask (Size) 883.00 (1)
Prev. Close 885.94
Today's Range 878.87 - 891.27
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga

Performance

YTD
+49.35%
+49.35%
1 Month
-7.53%
-7.53%
3 Month
-3.27%
-3.27%
6 Month
+16.29%
+16.29%
1 Year
+64.31%
+64.31%

More News

Read More
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
Via Benzinga
Is NYSE:LLY a Fit for high Growth Investing Strategies?
Via Chartmill
Eli Lilly Unusual Options Activity
Via Benzinga
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Via Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Via Benzinga
Exposures Product Safety
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Via Benzinga
This Is the Best Pharma Stock to Invest $1,000 in Right Now
Via The Motley Fool
Eli Lilly And Co DCF Valuation: Is The Stock Undervalued?
Via Talk Markets
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Via The Motley Fool
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
Via The Motley Fool
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Stocks To Buy And Hold For 5 Years
Via Talk Markets
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Via The Motley Fool
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
Via Investor's Business Daily
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
Via The Motley Fool
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Via Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Via Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Via Benzinga
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.